Raymond James maintains Veeva stock $285 target, Outperform rating

Raymond James reiterated an Outperform rating with a $285 price target on Veeva Systems following the company's Commercial Summit, citing the growth of Vault CRM to over 80 customers and positive feedback on its simpler, less expensive platform; this aligns with Veeva's reported 16.2% revenue growth to $2.75 billion and a 74.5% gross profit margin. While Salesforce is gaining traction with some large pharmaceutical firms due to its AI capabilities, Veeva's strong Q4 earnings, including a 14% revenue increase and 26% earnings rise, coupled with optimistic FY26 guidance and analysts' maintained Buy ratings and targets, suggest continued robust market positioning.

Analysis

Raymond James' reiteration of an Outperform rating and a $285 price target for Veeva Systems (VEEV) underscores the company's ongoing momentum, particularly the growth of its Vault CRM customer base to over 80, a notable increase from the 50+ previously reported. This operational success is mirrored in Veeva's financial performance, with last-twelve-months revenue growing 16.2% to $2.75 billion and a gross profit margin of 74.5%. Despite competitive pressures from Salesforce, which has secured contracts with Takeda and Pfizer citing customization and AI strengths, Veeva's Vault CRM is successfully attracting large pharmaceutical clients, with four of the top 20 now transitioning to its platform, often perceived as more cost-effective and simpler. Veeva's strong fourth-quarter earnings, featuring a 14% year-over-year revenue increase and a 26% rise in earnings, alongside an optimistic fiscal year 2026 guidance for 11% revenue and EPS growth, further solidify its market position. The company's strategic initiative, Veeva AI, set for a December 2025 launch, is anticipated to enhance its offerings, while InvestingPro data indicates a "GREAT" Financial Health score. However, the stock trades at a significant 53x earnings multiple, a factor to consider amidst positive analyst sentiment from firms like Stifel and Citi, who also maintain Buy ratings and positive outlooks.

Key Decisions for Investors

• Investors should acknowledge Veeva's strong customer acquisition momentum for Vault CRM and robust financial performance, including consistent revenue and earnings growth.
• It is prudent to monitor the evolving competitive dynamics with Salesforce, particularly concerning AI capabilities and large enterprise adoption choices within the pharmaceutical sector.
• The current valuation of 53x earnings should be carefully weighed against the company's growth trajectory, market penetration runway, and the positive financial health indicators highlighted by analysts.
• The upcoming launch of Veeva AI in December 2025 presents a potential long-term growth catalyst that warrants attention for its impact on Veeva's competitive edge.